41 matches for your search in the start-up spotlight
rssNoema Pharma is a clinical-stage biotech company advancing a portfolio of transformative therapeutics utilizing first-in-disease approaches targeting neuroscience-based conditions with high unmet need. Noema has four programs currently in active Phase 2 clinical trials evaluating pain in ...
Myria Biosciences is at the forefront of applying synthetic intelligence to transform drug development. The company's GEMMS (Genetically Engineered Modular Molecule Scaffolds) platform combines synthetic biology and artificial intelligence into a synthetic intelligence approach that allows the ...
ApiniLabs will revolutionize laboratory software by offering intelligent modular components, paving the way for a new era of lab solutions.
ApiniLabs will revolutionize laboratory software by offering intelligent modular components, paving the way for a new era of lab solutions.
NXI Therapeutics is a spin-off from the Biozentrum, University of Basel, Switzerland founded by Prof. Jean Pieters and CSO Dr. med. Rajesh Jayachandran. The company focuses on clinical applications in T cell-mediated autoimmune conditions and is committed to creating tomorrow’s disruptive ...
Bottneuro is developing non-invasive custom made tCS/EEG devices for diagnosis and treatment of neurological diseases. Our innovative method consists of capturing brainwave patterns for early intervention and performing multifocal electrical stimulation sessions of specific brain regions, ...
BioCopy is a multinational company and focuses on TCR(m)- based immuno-oncology drug development. The BioCopy group is headquartered in Switzerland. The German branch, including a state-of-the-art research and development facility, is situated in Emmendingen, north of Freiburg i. Br. We are ...
Mysthera Therapeutics AG was founded in Basel, Switzerland by Forty51 Ventures in 2023. Pursuing a first-in-class therapeutic approach, Mysthera plans to reshape the treatment landscape for autoimmune disease. PIM kinase inhibition uniquely and selectively modulates immune cell function in ...
The company brings together both scientific and operational expertise from various institutions in Switzerland and Germany and aims to become a world leading centre of excellence for novel vaccine development. RocketVax has its foundation in the ties between Swiss Rockets AG, a Swiss incubator ...